Status:
COMPLETED
CISCO-21 Prevent and Treat Long COVID-19.
Lead Sponsor:
NHS Greater Glasgow and Clyde
Collaborating Sponsors:
University of Glasgow
Chief Scientist Office of the Scottish Government
Conditions:
Covid19
Eligibility:
All Genders
Phase:
NA
Brief Summary
Many people have long-lasting symptoms after COVID-19, such as breathlessness, fatigue and chest pain. So far, research studies of treatments for COVID-19 have focused on the life-threatening acute il...
Detailed Description
The rationale for our study has two main parts. The first (primary) addresses a gap in therapy, notably, for a non-pharmacological intervention. To address this gap, the investigators have set out to ...
Eligibility Criteria
Inclusion
- Patients will be classified according by clinical presentation:
- A) Non-hospitalised - Positive diagnosis with persisting symptoms for at least 4 weeks from symptoms onset leading to medical review (A\&E, Community COVID Hub) but not admission (Treatment group), B) Hospitalised, positive diagnosis, and with post-discharge, persistent symptoms for at least 4 weeks from symptoms onset (Treatment group), C) Hospitalised, positive diagnosis, and in convalescent phase in-hospital (Prevention group).
- Groups A \& B = target population for treatment of persisting symptoms post-COVID i.e. Long-COVID; Group C = Target population for prevention of Long COVID.
- Virology PCR positive laboratory diagnosis and/or point of care test positive for COVID-and/or
- Positive Lateral Flow Test (confirmation from notes or by participant) and/or
- Positive COVID antibody test
- Persistent symptoms for at least 4 weeks from symptoms onset (Groups A \& B only)
- Presentation type - one of group A, B or C.
Exclusion
- Physiotherapy as part of standard care e.g. post intensive care unit (ICU), post high dependency unit (HDU),
- No expectation of being able to walk within 3 months
- Unable to provide informed consent,
- Unable to comply with the protocol.
- Known pregnancy
Key Trial Info
Start Date :
June 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 21 2025
Estimated Enrollment :
233 Patients enrolled
Trial Details
Trial ID
NCT04900961
Start Date
June 1 2021
End Date
February 21 2025
Last Update
February 25 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Queen Elizabeth University Hospital
Glasgow, United Kingdom
2
Royal Infirmary
Glasgow, United Kingdom